Evolution of the Average Target: Amrize AG

Evolution of the Target Price: Amrize AG

Changes in Analyst Recommendations: Amrize AG

b26ea437ae5f1e34438808c.NrgMRUfe0gLiSMDvINJ_cKSZOn-BzdXKeLRLQk27ibM.bP1gJDevlDCkcZeERJgYPunafxfbjJ2CNfcfNg71-cpljVYrL4-AaLFwkQ~5d34d27a88c623b2f3bb53c9af1d4c19
07-07 Truist Downgrades Amrize to Hold From Buy, Cuts Price Target to $48 From $65 MT
05-14 Morningstar Upgrades Amrize's Rating to Buy MT
05-01 Oppenheimer Adjusts Price Target on Amrize to $68 From $70, Maintains Outperform Rating MT
05-01 RBC Trims Price Target on Amrize to $60 From $61, Keeps Sector Perform Rating MT
02-26 On Field Investment Research Downgrades to Neutral Rating, Raises PT MT
02-23 Deutsche Bank Adjusts Amrize Price Target to $70 From $59, Maintains Buy Rating MT
02-20 Truist Raises Price Target on Amrize to $75 From $60, Keeps Buy Rating MT
02-19 RBC Capital Adjusts Price Target on Amrize to $61 From $60, Maintains Sector Perform Rating MT
02-19 Berenberg Adjusts Price Target on Amrize to $70 From $64, Maintains Buy Rating MT
02-19 Oppenheimer Adjusts Price Target on Amrize to $70 From $64, Maintains Outperform Rating MT
01-08 UBS Adjusts Price Target on Amrize to $57 From $53, Maintains Neutral Rating MT
12-08 Amrize Shares Fall After RBC Downgrade MT
12-08 RBC Downgrades Amrize to Sector Perform From Outperform, Lifts Price Target to $60 From $56 MT
11-26 Vertical Research Starts Amrize Coverage with Hold Rating MT
11-04 Oddo BHF Kicks Off Amrize Coverage with Neutral Rating MT
11-03 UBS Adjusts Price Target on Amrize to $53 From $52, Maintains Neutral Rating MT
25-10-29 Swiss stocks - Factors to watch on October 29 RE
25-10-28 On Field Investment Research Upgrades Amrize to Outperform, Raises PT MT
25-10-24 JPMorgan Kicks Off Amrize Coverage with Overweight Rating MT
25-10-24 Swiss stocks - Factors to watch on October 24 RE
25-10-21 Kepler Cheuvreux Kicks Off Amrize Coverage at Buy MT
25-10-14 UBS Adjusts Amrize Price Target to $52 From $49, Maintains Neutral Rating MT
25-10-08 Wells Fargo Initiates Amrize Coverage at Overweight MT
25-10-07 Barclays Kicks Off Amrize Coverage at Equalweight MT
25-09-12 The stock market regains its cloak of invincibility Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+35.06%
+11.04%
+16.53%
+26.04%
+17.97%
+16.31%
+14.11%
+17.38%
Average +19.31%
Weighted average by Cap. +21.81%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
51.31USD
Average target price
62.07USD
Spread / Average Target
+20.96%
High Price Target
71.70USD
Spread / Highest target
+39.73%
Low Price Target
51.97USD
Spread / Lowest Target
+1.28%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Truist Securities
Morningstar
Oppenheimer
RBC Capital Markets
On Field Investment Research
Deutsche Bank Securities
Berenberg Bank
UBS
Vertical Research
ODDO BHF
JPMorgan
Kepler Cheuvreux
Wells Fargo Securities
Barclays
Bernstein
BNP Paribas
Deutsche Bank Research
CIC Market Solutions
Morgan Stanley
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
51.31USD
Average target price
62.07USD
Spread / Average Target
+20.96%

Quarterly revenue - Rate of surprise